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TO THE EDITOR
In genetic counseling of autosomal rece-
ssive diseases, parents of patients are
normally informed on the basis of the
Mendelian principle that both parents
are asymptomatic heterozygous carriers
and the risk of recurrence is 25% in
subsequent pregnancies (Fassihi et al.,
2006). However, there are several exce-
ptions, including cases with uniparental
disomy (UPD). UPD is a condition in
which a pair of chromosomes are
inherited from only one parent
(Zlotogora, 2004). There are two types
of UPD, uniparental isodisomy and
uniparental heterodisomy (Zlotogora,
2004). When one chromosome is
present in duplicate, the situation is
described as isodisomy. When both
chromosomes from one parent are
present, the situation is heterodisomy
(Kotzot, 2001; Siegel and Slavotinek,
2005). Thus, homozygosity for a
recessive mutation may result from uni-
parental isodisomy. This study reports a
case of Netherton syndrome (NS, MIM
256500), an autosomal recessive
syndromic type of ichthyosis, showing
complete maternal isodisomy of chro-
mosome 5 with a pathogenic mutation
in serine protease inhibitor Kazal-type 5
(SPINK5; Bitoun et al., 2002; Sun and
Linden, 2006).
The patient was a 10-year-old Japa-
nese girl, whose clinical and histopatho-
logical details have been described
recently (Akagi et al., 2013). In brief,
she demonstrated typical symptoms of
NS, including ichthyosiform erythro-
derma, bamboo hairs, and atopic
features (Figure 1a and b). She showed
moderate disease severity without any
additional extracutaneous abnormalities.
See Supplementary Data for further clin-
ical information.
All described studies were performed
following the guidelines of the medical
ethical committee of Kurume University
School of Medicine. Written informed
consent was obtained from each indivi-
dual, and the study was conducted
according to the Declaration of Helsinki
Principles.
Direct nucleotide sequencing of exon
19 of SPINK5 for the patient’s genomic
DNA disclosed a recurrent homozygous
mutation p.Arg578X (Figure 1c). How-
ever, although the mother was a hetero-
zygous carrier of this mutation, theAccepted article preview online 16 September 2013; published online 17 October 2013
Abbreviations: CP, crossing point; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; NS, Netherton
syndrome; SPINK5, serine protease inhibitor Kazal-type 5; UPD, uniparental disomy
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father showed a wild-type sequence
(Figure 1c). Polymorphism analysis of
SPINK5 between intron 2 and intron 27
indicated that all five polymorphisms
examined were homozygous, although
only three of them were fully informa-
tive (Table 1).
To verify whether the patient had a
gene deletion in SPINK5, we examined
the gene copy number of this family
using real-time quantitative PCR for
exons 15, 19, and 21. Each crossing-
point (CP) value was compared with that
of glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) by the relative
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Figure 1. Clinical features and results of genetic analysis of our patient with Netherton syndrome. (a) Clinical features of the patient. Whitish thin scales and
diffuse erythemas were present on legs at the age of 10 years. (b) Light microscopic analysis showed trichorrhexis invaginata (bamboo hair). (c) Nucleotide
sequencing revealed homozygous mutation p.Arg578X in the patient. (d) Genomic copy-number quantification of present family. The patient and the parents did
not show deletion of these exons, and no genomic copy-number alteration at SPINK5 region in the patient was indicated. (e) Scheme of chromosome 5 and
positions of 14 microsatellite markers. (f) Pedigree and results of genotype analysis in chromosome 5 and other six chromosomes of the patient and the parents. The
patient has complete maternal isodisomy of chromosome 5.
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quantification system and corrected CP
values were used for the evaluation of
copy numbers. The patient and her
parents did not show deletion of these
exons, and no reduced genomic copy
number at SPINK5 region was observed
(Figure 1d).
The origin of the second mutant allele
in the patient was studied by genotype
analysis of 14 microsatellite markers
spanning the entire chromosome 5
(ABI Prism Linkage Mapping Set Version
2.5, Applied Biosystems, Warrington,
UK; Figure 1e). The patient was homo-
zygous for all 14 markers, nine of which
indicated inheritance of two copies
of maternal chromosome 5 (Figure 1f).
The allele sizes were analyzed using
GeneMapper software (Applied Bio-
systems). In addition, normal segrega-
tion seen in six non-chromosome 5
markers (D1S2667, D6S1577, D11S987,
D16S515, D21S914, and DXS987)
excluded non-paternity (Figure 1f). Finally,
karyotyping of peripheral blood from the
patient revealed 46, XX. The results of all
studies indicated that our NS case was
caused by complete maternal isodisomy
of chromosome 5.
There are 40 reported cases of various
autosomal recessive diseases caused by
UPD, including three cases with genes
on chromosome 5 (Engel, 2006). The
first case of spinal muscular atrophy
(MIM 253300) was caused by comp-
lete paternal isodisomy of chromosome
5. The second case of child-onset schiz-
ophrenia (MIM 181500) was caused by
segmental paternal isodisomy of 5q32-
qter. The third case of NS was caused by
a homozygous missense mutation
p.Arg267Glu in SPINK5, resulting from
a de novo mutation in combination with
segmental maternal isodisomy (Lin
et al., 2007). To our knowledge, com-
plete maternal isodisomy of chromo-
some 5 with a pathogenic SPINK5
mutation is previously unreported, and
this is the fourth case of UPD in
chromosome 5, including one previous
NS case (Lin et al., 2007).
Depending on the source of the par-
ental chromosome, UPD gives rise to
unique phenotypes, and the phenom-
enon is known as genomic imprinting.
To date, an association of genomic
imprinting with intrauterine growth retar-
dation, developmental delay, and redu-
ced stature has been reported (Miozzo
and Simoni, 2002; Coan et al., 2005).
UPD is induced by diverse mechan-
isms, including gamete complementa-
tion, trisomy rescue, monosomy rescue,
and post-fertilization error (Robinson,
2000). As common processes, trisomy
rescue causes heterodisomy, in which
both chromosomes from one parent are
present, or monosomy rescue causes
isodisomy, in which one chromo-
some is present in duplicate. In mono-
somy rescue, a nullisomic gamete is
fertilized with a haploid gamete. The
single chromosome from the other
parent is duplicated and produces iso-
disomy of the chromosome. Because
most monosomies are lethal and result
in spontaneous abortion in the early
stage of pregnancy, monosomy rescue
is considered to occur early after ferti-
lization (Fassihi et al., 2006). The most
likely cause of UPD in our patient is
fertilization of a normal egg by a nulli-
somic sperm with subsequent salvage of
a monosomy by post-fertilization dupli-
cation of the maternal chromosome 5,
resulting in homozygosity for the
SPINK5 locus containing the mutation
p.Arg578X (Kotzot and Utermann,
2005). Although UPD is a rare cause of
autosomal recessive disorder, it is
important. Therefore, it is important
that DNA samples are obtained from
both the patient and the parents in
mutation analysis for autosomal
recessive conditions.
In summary, to our knowledge, com-
plete maternal isodisomy in chromo-
some 5 was previously unreported and
was the fourth case of UPD in chromo-
some 5. As the patient did not have any
symptoms other than those seen in NS,
we speculate that genes on chromo-
some 5 are not imprinted. However, a
careful follow-up for possible late-onset
symptoms should be necessary. Our
findings should provide important impli-
cations into mutation screening and
genetic counseling in NS.
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Table 1. Haplotype analysis of SPINK5 using five intragenic polymorphisms
Location Nucleotide position1 Major allele Minor allele Father Patient Mother
Intron 2 82  31 G A G/G G/G G/G
Exon 13 1,157 G A G/G A/A A/A
Intron 18 1,693 32 T C C/C T/T T/C
Exon 26 2,475 G T G/G T/T T/G
Intron 27 2,666 þ13 T A A/A A/A A/A
1According to SPINK5 gene sequence, GenBank accession no. NM_001127698.
S Numata et al.
Complete Maternal Isodisomy of Chromosome 5
www.jidonline.org 851
REFERENCES
Akagi A, Kitih A, Moniaga C et al. (2013) A case of
Netherton syndrome with an elevated serum
TARC level. J Dermatol 40:752–3
Bitoun E, Chavanas S, Irvine AD et al. (2002)
Netherton syndrome: disease expression and
spectrum of SPINK5 mutations in 21 families.
J Invest Dermatol 118:352–61
Coan PM, Burton GJ, Ferguson-Smith AC (2005)
Imprinted genes in the placenta–a review.
Placenta 26(Suppl A):S10–20
Engel E (2006) A fascination with chromosome
rescue in uniparental disomy: Mendelian
recessive outlaws and imprinting copyrights
infringements. Eur J Hum Genet 14:1158–69
Fassihi H, Lu L, Wessagowit V et al. (2006)
Complete maternal isodisomy of chromosome
3 in a child with recessive dystrophic epider-
molysis bullosa but no other phenotypic
abnormalities. J Invest Dermatol 126:2039–43
Kotzot D (2001) Complex and segmental unipar-
ental disomy (UPD): review and lessons from
rare chromosomal complements. J Med Genet
38:497–507
Kotzot D, Utermann G (2005) Uniparental disomy
(UPD) other than 15: phenotypes and bibliogra-
phy updated. Am J Med Genet A 136:287–305
Lin SP, Huang SY, Tu ME et al. (2007) Netherton
syndrome: mutation analysis of two Taiwa-
nese families. Arch Dermatol Res 299:145–50
Miozzo M, Simoni G (2002) The role of imprinted
genes in fetal growth. Biol Neonate 81:
217–28
Robinson WP (2000) Mechanisms leading to uni-
parental disomy and their clinical conse-
quences. Bioessays 22:452–9
Siegel DH, Slavotinek A (2005) Uniparental dis-
omy. Pediatr Dermatol 22:482–7
Sun JD, Linden KG (2006) Netherton syndrome: a
case report and review of the literature. Int J
Dermatol 45:693–7
Zlotogora J (2004) Parents of children with auto-
somal recessive diseases are not always car-
riers of the respective mutant alleles. Hum
Genet 114:521–6
IL-17A RNA Aptamer: Possible Therapeutic Potential in
Some Cells, More than We Bargained for in Others?
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TO THE EDITOR
IL-17A is one of the main pathogenic
factors orchestrating inflammation in
diseases such as psoriasis and rheuma-
toid arthritis (Martin et al., 2012).
Although effective therapies already
exist for these diseases, biologics are
restricted to severely affected patients
due to the considerable costs of current
antibody-based therapies and potential
systemic immunosuppressive and drug-
induced side effects. New topical strate-
gies are therefore required for chronic
inflammation.
Aptamers are considerably cheaper
to produce and furthermore are non-
immunogenic. The use of stable RNA
aptamers for therapy is based on their
ability to fold into unique 3-dimensional
structures that bind to the target with
high specificity and affinity. The first
aptamer-based therapeutic agent, which
targets vascular endothelial growth
factor (Huang et al., 2001), was FDA-
approved in 2004 for treatment of
macular degeneration and several other
aptamers are currently in clinical trials
(Zhou et al., 2012).
Here, we have sought to show the
functional efficacy of a previously des-
cribed aptamer, termed Apt21-2, which
blocks IL-17A binding to its receptor
(Ishiguro et al., 2011). So far, the func-
tional properties of this aptamer have
not been investigated in human patho-
physiological settings. To overcome this
lack of information we analyzed the
efficacy of Apt21-2 in a co-culture
system, which mimics psoriatic inflam-
mation, using T cells isolated from
healthy controls and psoriatic patients.
All human samples were taken in
accordance with the Declaration of
Helsinki Principles, and participants
gave their written informed consent
(ethics approval for this study is covered
by IRAS REC number: 11/YH/0368). This
in-vitro model, using patient-derived and
healthy cells, is based on our own
previous work (Muhr et al., 2010) with
blood-derived IL-17 producers (CD4þ
CCR6þ T cells) activated with TCR
stimulatory antibodies (antiCD3 and
antiCD28; Biolegend, Hatfield, UK).
These cells were co-cultured with
healthy human primary fibroblasts. The
protocols used for the culture of primary
human skin cells are also based on
previous work (Wittmann et al., 2012).
To measure the functional response, a
bead-based ELISA assay (FlowCytomix;
eBioscience, Hatfield, UK) in addition to
an IL-6 and IL-8 ELISA (DuoSet human
ELISA kit; R&D Systems, Abingdon, UK)
was used. IL-17A (Biolegend)-mediated
production of IL-6 was determined to
establish the efficacy of the aptamer, as
this has been employed in the previously
published work (Ishiguro et al., 2011) and
we have extended this to include IL-8. It
is well known that both keratinocytes and
fibroblasts produce IL-6 and IL-8.
Our results confirmed that IL-6
release in recombinant IL-17A-treated
fibroblasts can be significantly abro-
gated in a dose-dependent fashion by
addition of Apt21-2, and this effect
was not seen when a control aptamer
(synthesized to the polymerase from
foot-and-mouth disease virus, 47tr;
Ellingham et al., 2006) was used
(Figure 1a). The effect was also not
present if recombinant tumor necrosis
factor-a (Immunotools, Friesoythe,
Germany) was used as a stimulus
(Figure 1b). The same effect was con-
firmed for fibroblasts isolated from psor-
iatic patients (data not shown). Higher
doses of IL-17A were used and an
efficient inhibitory effect of IL-6 produc-
tion could be seen in doses up to
20 ng ml1. However, the aptamer
failed to consistently neutralize the
effect of 40 ng ml 1 of rIL-17A on IL-6
production in fibroblasts. In a co-culture
system of healthy fibroblasts and healthy
or psoriatic CD4þCCR6þ T cells, a
neutralizing capacity of Apt21-2 wasAccepted article preview online 20 September 2013; published online 24 October 2013
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